Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Submitted by Anonymous (not verified) on 25 November 2025 - 13:00
Product Management Service (PMS) – Frequently Asked Questions (FAQs)
Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 25 November 2025 - 10:35
Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 25 November 2025 - 10:20
Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 6, Status: Authorised
Scientific recommendations on classification of advanced therapy medicinal products
Submitted by Anonymous (not verified) on 25 November 2025 - 10:17
Scientific recommendations on classification of advanced therapy medicinal products
Minutes of the COMP meeting 7-8 October 2025
Submitted by Anonymous (not verified) on 25 November 2025 - 10:03
Minutes of the COMP meeting 7-8 October 2025
Step-by-step guide: How to evaluate a CT application - CTIS Training Programme - Module 06
Submitted by Anonymous (not verified) on 25 November 2025 - 10:01
Step-by-step guide: How to evaluate a CT application - CTIS Training Programme - Module 06
European Medicines Agency’s data protection notice for PMS user acceptance stakeholder involvement
Submitted by Anonymous (not verified) on 25 November 2025 - 9:43
European Medicines Agency’s data protection notice for PMS user acceptance stakeholder involvement
Human medicines European public assessment report (EPAR): Pedea, ibuprofen, Date of authorisation: 28/07/2004, Revision: 18, Status: Authorised
Submitted by Anonymous (not verified) on 25 November 2025 - 9:15
Human medicines European public assessment report (EPAR): Pedea, ibuprofen, Date of authorisation: 28/07/2004, Revision: 18, Status: Authorised
Accessibility
Submitted by Anonymous (not verified) on 25 November 2025 - 9:00
Accessibility
Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 24 November 2025 - 16:45
Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 15, Status: Authorised